Vonvendi
Vonvendi ingredients
| Active ingredient | Strength |
|---|---|
| Von willebrand factor (recombinant) | see label |
What Vonvendi is used for
The FDA lists the approved uses on the official label (below). In the EU, human coagulation factor VIII / human von willebrand factor is approved as Voncento for:
Von Willebrand disease (VWD) Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Haemophilia A (congenital factor-VIII deficiency) Prophylaxis and treatment of bleeding in patients with haemophilia A.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Vonvendi
- Generic name
- Von willebrand factor (recombinant)
- Made by
- Takeda Pharmaceuticals America, Inc.
- Forms
- Kit
- FDA approval
- Biologic licence (BLA) BLA125577
- On the US market since
- 2015
Official information
- MedlinePlus drug information (search for Von willebrand factor (recombinant))
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vonvendi?
Vonvendi (Von willebrand factor (recombinant)) is a specialist medicine made by Takeda Pharmaceuticals America, Inc., approved by the US FDA.
What are the ingredients of Vonvendi?
Vonvendi contains Von willebrand factor (recombinant).
Is Vonvendi approved in Europe?
The same active substance is approved in the EU as Voncento.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA